2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists

US6984643B2 · kind B2 · utility

Assignee

• Roche Palo Alto LLC · US

Inventors

• Daisy Joe Du Bois · Palo Alto, US
• Long Mao · San Diego, US
• Daniel Rogers · San Diego, US
• John Williams · San Diego, US

Key dates

• Filing date: Jul 1, 2003
• Grant date: Jan 10, 2006
• Expiry date: Dec 5, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of Formula (I): wherein Ar1 is aryl; Ar2 is hydrogen, cycloalkyl, aryl or heteroaryl; Z is —C(═O) or a single bond; R1, R2, R3, R4 and R5 are independently hydrogen or alkyl optionally substituted with hydroxy; alk is an alkylene chain of one to six carbon atoms; X is —O—, —NRh (where Rh is hydrogen or alkyl), (CR6R7)m(where R6 and R7 are independently in each occurrence hydrogen or alkyl and m is an integer from 0 to 3), or —S(O)n (wherein n is an integer from 0 to 2); or prodrugs thereof, and pharmaceutically acceptable salts thereof,are inhibitors of CCR3 useful for treating eosinophil induced diseases such as asthma.